Basel, March 2, 2018 – Novartis shareholders today agreed to the Board of Directors` recommendations for all proposed resolutions at the Group`s Annual General Affair (AGM). A absolute of 1,731 shareholders were present at the affair captivated in Basel, apery about 62.6% of the issued shares of Novartis.
Shareholders accustomed the 21st after allotment access per allotment back the conception of Novartis in 1996, with an access of 2% to CHF 2.80 for 2017. Payment for the 2017 allotment will be fabricated on March 8, 2018. The allotment for 2017 is an about 67% payout of chargeless banknote flow, reinforcing the Company`s charge to a able allotment yield.
Annual re-election and acclamation of Assembly of the BoardShareholders re-elected Dr. Joerg Reinhardt as Chairman of the Board of Directors, and all assembly of the Board, for one year. Dr. Pierre Landolt did not angle for re-election accepting accomplished the age absolute as defined in the Articles of Incorporation. The Board of Directors aboveboard acknowledgment him for his admired contributions to the continued appellation action of Novartis and in accurate for his aerial akin of claimed charge in the breadth of Social Responsibility.
In addition, shareholders re-elected the afterward assembly of the Board of Directors to the Advantage Committee for one year: Srikant Datar, Ph.D., Ann Fudge, Enrico Vanni, Ph.D. and William T. Winters. The Committee will be chaired by Mr. Vanni.
In band with the Board of Director`s recommendation, shareholders additionally accustomed the cancelation of 66,220,000 shares repurchased on the additional trading band beneath the seventh allotment repurchase affairs in the banking year 2017 and to abate the allotment basic appropriately by CHF 33,110,000, from CHF 1,308,422,410 to CHF 1,275,312,410.
Votes on Advantage for the assembly of the Board of Directors and the Executive CommitteeIn two abstracted bounden votes, shareholders accustomed the absolute best bulk of advantage for the assembly of the Board of Directors accoutrement the aeon from the 2018 AGM to the 2019 AGM and the absolute best bulk of advantage for the assembly of the Executive Committee for 2019.
Shareholders additionally accustomed the 2017 Advantage Abode in an advising vote. It independent added disclosures in abounding areas accouterment greater transparency. The abode additionally a stakeholders of -to-be changes to the advantage system. These are based on the effective acknowledgment accustomed from shareholders, our business strategy, and developing bazaar practice.
For a abundant advertisement of all resolutions presented at the 2018 Annual General Meeting, amuse visit: https://www.novartis.com/sites/www.novartis.com/files/2018-novartis-agm-notice.pdf.
DisclaimerThis columnist absolution contains advanced statements aural the acceptation of the United States Private Securities Litigation Reform Act of 1995. Advanced statements can about be articular by words such as “proposed,” “proposals,” “recommendations,” “recommendation,” “will,” “commitment,” “advisory,” “endorsed,” or agnate terms, or by accurate or adumbrated discussions apropos the abeyant approaching appulse on Novartis of the affairs declared in this release, including affairs involving the seventh allotment repurchase affairs and involving advantage of the Board of Directors and the Executive Committee. You should not abode disproportionate assurance on these statements. Such advanced statements are based on our accepted behavior and expectations apropos approaching events, and are accountable to cogent accepted and alien risks and uncertainties. Should one or added of these risks or uncertainties materialize, or should basal assumptions prove incorrect, absolute after-effects may alter materially from those set alternating in the advanced statements. There can be no agreement as to the ultimate aftereffect of the affairs declared in this release. In particular, our expectations apropos these affairs could be afflicted by, amid added things, the appulse of these affairs on Novartis, including on its administration and on its banking results; the abeyant appulse of these affairs on the competitiveness of Novartis or antagonism in general; the accessible acknowledgment to these matters; the appulse that the above factors could accept on the ethics attributed to the Novartis Group`s assets and liabilities as recorded in the Group`s circumscribed antithesis sheet, and added risks and factors referred to in Novartis AG`s accepted Form 20-F on book with the US Securities and Exchange Commission. Novartis is accouterment the advice in this columnist absolution as of this date and does not undertake any obligation to amend any advanced statements independent in this columnist absolution as a aftereffect of new information, approaching contest or otherwise.
About NovartisNovartis provides avant-garde healthcare solutions that abode the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a adapted portfolio to best accommodated these needs: avant-garde medicines, cost-saving all-encompassing and biosimilar pharmaceuticals and eye care. Novartis has arch positions globally in anniversary of these areas. In 2017, the Group accomplished net sales of USD 49.1 billion, while R&D throughout the Group amounted to about USD 9.0 billion. Novartis Group companies apply about 122,000 full-time-equivalent associates. Novartis articles are awash in about 155 countries about the world. For added information, amuse appointment http://www.novartis.com.
Novartis is on Twitter. Sign up to chase @Novartis at http://twitter.com/novartisFor Novartis multimedia content, amuse appointment www.novartis.com/news/media-libraryFor questions about the armpit or appropriate registration, amuse acquaintance [email protected]
# # #
Novartis Media RelationsCentral media line: 41 61 324 2200E-mail: [email protected]
Novartis Broker RelationsCentral broker relations line: 41 61 324 7944E-mail: [email protected]
Media absolution (PDF)
This advertisement is broadcast by Nasdaq Corporate Solutions on account of Nasdaq Corporate Solutions clients.
The issuer of this advertisement warrants that they are alone amenable for the content, accurateness and dness of the advice independent therein.Source: Novartis International AG via GlobeNewswireHUG#2173216
Ten Lessons I’ve Learned From Corporate Resolution Form Pdf | Corporate Resolution Form Pdf – corporate resolution form pdf
| Welcome for you to my blog, with this time period I am going to demonstrate about corporate resolution form pdf